Study Summary
This trial is to find out the benefits and side effects of two drugs, osimertinib and tegavivint, in treating patients with lung cancer that has spread to other places in the body.
- Malignant Neoplasms
- Metastatic Lung Non-Small Cell Carcinoma
- Stage IVA Lung Cancer AJCC v8
- Stage IVB Lung Cancer AJCC v8
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 4 Secondary · Reporting Duration: Up to 4 years
Trial Safety
Safety Progress
Side Effects for
Trial Design
1 Treatment Group
Treatment (osimertinib, tegavivint)
1 of 1
Experimental Treatment
18 Total Participants · 1 Treatment Group
Primary Treatment: Osimertinib · No Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:About The Reviewer
Michael Gill - B. Sc.
First Published: October 17th, 2021
Last Reviewed: November 22nd, 2022
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.